Boston Scientific Corp. has gained U.S. Food and Drug Administration approval for a software upgrade to a “patient management” system.
The Natick-based medical device firm said the system allows physicians to monitor cardiac device patients remotely. The remote monitoring includes patients’ follow-up data.
The system can detect changes in a patient’s heart between scheduled follow-up visits and send data and alerts directly to physicians.
The software improvements approved by the FDA were made in response to physician feedback, the company said.
